

## 

**Citation:** Nkuipou-Kenfack E, Schanstra JP, Bajwa S, Pejchinovski M, Vinel C, Dray C, et al. (2017) The use of urinary proteomics in the assessment of suitability of mouse models for ageing. PLoS ONE 12(2): e0166875. doi:10.1371/journal. pone.0166875

Editor: Jayoung Kim, Cedars-Sinai Medical Center, UNITED STATES

Received: May 10, 2016

Accepted: November 4, 2016

Published: February 15, 2017

**Copyright:** © 2017 Nkuipou-Kenfack et al. This is an open access article distributed under the terms of the <u>Creative Commons Attribution License</u>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD005229.

**Funding:** The project was partly funded by grant GA 31354 (CodeAge) FP7-PEOPLE-2011-ITN program (to HM and ENK), BMBF Gerontosys II project (NephAge, 031 5896A) (to PZ, MB, WBW and TBH), by a Marie Curie EU grant (CIG 293568) (to WBW), by the Margarete von Wrangell Habilitationsprogramm, (Ministerium für RESEARCH ARTICLE

# The use of urinary proteomics in the assessment of suitability of mouse models for ageing

Esther Nkuipou-Kenfack<sup>1,2</sup>, Joost P. Schanstra<sup>3,4</sup>, Seerat Bajwa<sup>5</sup>, Martin Pejchinovski<sup>1</sup>, Claire Vinel<sup>3,4</sup>, Cédric Dray<sup>3,4</sup>, Philippe Valet<sup>3,4</sup>, Jean-Loup Bascands<sup>6</sup>, Antonia Vlahou<sup>7</sup>, Thomas Koeck<sup>1</sup>, Melanie Borries<sup>8,9</sup>, Hauke Busch<sup>8,9</sup>, Wibke Bechtel-Walz<sup>10</sup>, Tobias B. Huber<sup>11,12,13</sup>, Karl L. Rudolph<sup>5</sup>, Andreas Pich<sup>2</sup>, Harald Mischak<sup>1,14</sup>, Petra Zürbig<sup>1</sup>\*

 Mosaiques Diagnostics GmbH, Hannover, Germany, 2 Hannover Medical School, Core Facility Proteomics, Hannover, Germany, 3 Institut National de la Santé et de la Recherche Médicale (INSERM), U1048, Institut of Cardiovascular and Metabolic Disease, Toulouse, France, 4 Université Toulouse III Paul-Sabatier, Toulouse, France, 5 Leibniz Institute of Age Research, Fritz Lipmann Institute, Jena, Germany, 6 Inserm-UMR Diabète athérothrombose Thérapies Réunion Océan Indien (DéTROI), plateforme CYROI, Sainte-Clotilde, France, 7 Biotechnology Division, Biomedical Research Foundation Academy of Athens, Athens, Greece, 8 Systems Biology of the Cellular Microenvironment Group, Institute of Molecular Medicine and Cell Research, Albert-Ludwigs-University, Freiburg im Breisgau, Germany, 9 German Cancer Consortium (DKTK), Freiburg and German Cancer Research Center (DKFZ), Heidelberg, Germany, 10 University Hospital Freiburg, Freiburg, Germany, 11 Department of Medicine IV, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg, Germany, 12 BIOSS Center for Biological Signalling Studies, Albert-Ludwigs-University Freiburg, Germany, 13 Center for Systems Biology (ZBSA) and Freiburg Institute for Advanced Studies (FRIAS), Albert-Ludwigs-University Freiburg, Freiburg, Germany, 14 BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom

\* zuerbig@mosaiques-diagnostics.com

### Abstract

Ageing is a complex process characterised by a systemic and progressive deterioration of biological functions. As ageing is associated with an increased prevalence of agerelated chronic disorders, understanding its underlying molecular mechanisms can pave the way for therapeutic interventions and managing complications. Animal models such as mice are commonly used in ageing research as they have a shorter lifespan in comparison to humans and are also genetically close to humans. To assess the translatability of mouse ageing to human ageing, the urinary proteome in 89 wild-type (C57BL/6) mice aged between 8–96 weeks was investigated using capillary electrophoresis coupled to mass spectrometry (CE-MS). Using age as a continuous variable, 295 peptides significantly correlated with age in mice were identified. To investigate the relevance of using mouse models in human ageing studies, a comparison was performed with a previous correlation analysis using 1227 healthy subjects. In mice and humans, a decrease in urinary excretion of fibrillar collagens and an increase of uromodulin fragments was observed with advanced age. Of the 295 peptides correlating with age, 49 had a strong homology to the respective human age-related peptides. These ortholog peptides including several collagen (N = 44) and uromodulin (N = 5) fragments were used to generate an ageing classifier that was able to discriminate the age among both wild-type mice and healthy subjects. Additionally, the ageing classifier depicted that telomerase knock-out



Wissenschaft Baden-Württemberg) (to WBW), by the Mathilde-Wagner-Habilitationspreis (to WBW), by the German Research Foundation (DFG): CRC 992 (to TBH) and Heisenberg program (to TBH), by the European Research Council-ERC grant 616891 (to TBH); by the BMBF-STOP-FSGS 01GM1518C (to TBH), and by the Excellence Initiative of the German Federal and State Governments (EXC294, BIOSS II to TBH). The funders provided support in the form of salaries for authors [ENK, SB, MP, TK, MB, WBW, TBH, KLR, HM and PZ], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.

**Competing interests:** The authors have declared the following potential conflict of interest: H. Mischak is the founder and co-owner of Mosaiques Diagnostics GmbH, who developed the CE-MS technology for clinical application. E. Nkuipou-Kenfack, M. Pejchinovski, T. Koeck, P. Zürbig are employees of Mosaiques Diagnostics GmbH. This does not alter our adherence to PLOS ONE policies on sharing data and materials. mice were older than their chronological age. Hence, with a focus on ortholog urinary peptides mouse ageing can be translated to human ageing.

#### Introduction

During a lifetime, a number of molecular and cellular insults accumulate and lead to ageing [1]. Ageing is therefore a complex process characterised by a systemic and progressive deterioration of biological functions, leading to impaired tissue function thus increasing the likelihood of death. The burden caused by age-related diseases is prominent and prone to increase over the years. As life expectancy increases, improving health in the elderly population will be pivotal in dealing with subsequent enormous socio-economic challenges as a consequence of this improved longevity [2]. There is therefore an urgency to develop intervention strategies that will improve management of co-morbidities associated with ageing. Management of complications associated with ageing can firstly be accomplished by understanding molecular mechanisms associated with healthy ageing.

In ageing research, human studies are rare due to limiting factors mainly pertaining to the challenge in obtaining tissue samples from apparently healthy subjects [3]. As a result, animal models including mouse models have mostly been used due to obvious factors including shorter life span and the ease of obtaining samples in comparison to humans. A major concern of using animal models is the ability (or the lack thereof) to translate results to humans [4]. We have previously reported the benefit of using urinary proteome analysis in the screening of suitable animal models for human diseases [5,6]

In the present study our aim was to investigate if findings in ageing research using mouse models can be translated to humans using urinary proteome (naturally occurring peptides of less than 20 kDa) analysis. The use of urinary proteome analysis allows obtainment, in a non-invasive manner, of information on ageing. We have previously shown this in a number of studies which included over 1200 healthy individuals [7,8]. Comparison of human and mouse age-related urinary proteomes should provide unique insight in the translatability of mouse models of ageing.

#### Materials and methods

#### Mice

Mice urine samples were obtained from wild-type C57BL/6 strains (N = 89). These mice included 4 weeks (N = 13), 12 weeks (N = 15), 48 weeks (N = 28), 61 weeks (N = 5), 84 weeks (N = 13) and 96 weeks (N = 15) old mice that were purchased from Janvier Labs, France. Additionally, 61 weeks old telomerase knock-out (Terc<sup>-/-</sup>) mice samples (N = 5) were originally generated by injecting mTR -/- WW6 ES cells to C57BL/6 recipients and were maintained since their generation in 1997 on this C57BL/6 background by in-house breeding [9,10]. All animal experiments were conducted in accordance with the German Law for the welfare of animals and were approved by the committee from the "Regierungspräsidium Freiburg" (approval number: 35-9185.81/G-11/51).

#### Humans

To compare mouse ageing with human ageing, we have used the 1227 healthy subjects previously described in a human ageing study [7]. For the definition and validation of an ageing

support vector machine (SVM) classifier (see Results), a training set of 50 subjects was established by randomly selecting young and old healthy subjects within this cohort of 1227 healthy subjects. For the definition of the SVM classifier young healthy subjects were considered to be between 20–39 years (N = 25) whereas older subjects were considered over 60 years (N = 25). An independent test set was also randomly selected to validate the SVM classifier and it comprised of young (20–39; N = 20), mature (40–59; N = 20) and old healthy subjects (60 and over; N = 20). The study was performed in accordance with the ethical principles in the Declaration of Helsinki and Good Clinical Practice. All datasets were derived from previous studies and were anonymised. The study was approved by the local ethics committee (approval number: 3185–2016).

#### Sample preparation and proteome analysis

The proteomic analysis based on capillary electrophoresis coupled to mass spectrometry (CE-MS) for human urine samples has already been published [7]. For mouse proteomic analysis, a 150  $\mu$ l aliquot of mice urine was thawed immediately before use and diluted with 150  $\mu$ l of 2 M urea, 10 mM NH<sub>4</sub>OH containing 0.02% SDS. To remove higher molecular mass proteins, such as albumin and immunoglobulin G, the sample was ultra-filtered using Centrisart ultracentrifugation filter devices (20 kDa MWCO; Sartorius, Goettingen, Germany) until filtrate was obtained. This filtrate was then applied onto a PD-10 desalting column (GE Healthcare, Uppsala, Sweden) equilibrated in 0.01% NH<sub>4</sub>OH in HPLC-grade in H<sub>2</sub>O (Roth, Germany) to decrease matrix effects by removing urea, electrolytes, salts, and to enrich polypeptides present. Finally, all samples were lyophilised, stored at 4°C, and suspended in HPLC-grade H<sub>2</sub>O shortly before capillary electrophoresis coupled to mass spectrometry (CE-MS) analyses, as described [7].

CE-MS analyses were performed using a P/ACE MDQ capillary electrophoresis system (Beckman Coulter, Fullerton, USA) on-line coupled to a microTOF MS (Bruker Daltonics, Bremen, Germany) as described previously [11,12]. The ESI sprayer (Agilent Technologies, Palo Alto, CA, USA) was grounded, and the ion spray interface potential was set between -4 and -4.5 kV. Data acquisition and MS acquisition methods were automatically controlled by the CE via contact-close-relays. Spectra were accumulated every 3 s, over a range of m/z 350 to 3000. Accuracy, precision, selectivity, sensitivity, reproducibility, and stability of the CE-MS measurements were demonstrated elsewhere [11].

#### Peptide sequencing

For sequencing, processed urine samples were separated on a Dionex Ultimate 3000 RSLS nano flow system (Dionex, Camberly UK). A 5 ml sample was loaded onto a Dionex 5 mm C18 nano trap column at a flow rate of 5 ml/min. Elution was performed on an Acclaim Pep-Map 75 mm C18 nano column over 100 min. The sample was ionised in positive ion mode using a Proxeon nano spray ESI source (Thermo, Fisher Hemel UK) and analysed in an Orbi-trap Velos FTMS (Thermo Finnigan, Bremen, Germany). The MS was operated in data-dependent mode to switch between MS and MS/MS acquisition and parent ions were fragmented by (high-) energy collision-induced dissociation and also electron transfer dissociation. Data files were searched against *Mus musculus* entries in the Swiss-Prot database with Proteome Discoverer version 1.2 (Thermo Fisher Scientific, Bremen) with SEQUEST spectral algorithm. No fixed modification and oxidation of methionine as variable modifications were selected. Mass error windows of 10 ppm for MS and 0.05 Da (HCD; high resolution) or 0.5 Da (CID, ETD; low resolution) for MS/MS were allowed. For further validation of obtained peptide identification, the strict correlation between peptide charge at pH 2 and CE-migration

time was utilised to minimise false-positive identification rates [13]. Calculated CE migration time of the sequence candidate based on its peptide sequence (number of basic amino acids) was compared to the experimental migration time. Peptides were accepted only if they had a mass deviation below  $\pm$  80 ppm and a CE-migration time deviations below  $\pm$  2 min. Only sequenced peptides were considered for further investigation.

#### Data processing

Mass spectral peaks representing identical molecules at different charge states were deconvoluted into single masses using MosaiquesVisu software [14]. Only signals with z>1 observed in a minimum of three consecutive spectra with a signal-to-noise ratio of at least four were considered. CE-MS data were calibrated using 150 reference mass data points and 452 reference migration time data points by locally weighted regression. For normalisation of analytical and urine dilution variances, signal intensities were normalised relative to 29 internal standard peptides [15]. The obtained peak lists characterise each peptide by its molecular mass [Da], normalised CE migration time [min] and normalised signal intensity. All detected peptides were deposited, matched, and annotated in a Microsoft SQL database allowing further statistical analysis [16]. For clustering, peptides in different samples were considered identical if mass deviation was <50 ppm for small (<4,000 Da) or 75 ppm for larger peptides. Acceptable migration time deviation was, <  $\pm$  1 minutes for 19 min, gradually increasing to, <  $\pm$  2.5 min at 50 min. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE [17] partner repository with the dataset identifier PXD005229.

#### Correlation analysis and development of a high dimensional model

As peptide profiles across the samples were not normally distributed, a correlation analysis was performed for peptide discovery using the non-parametric Spearman's rank coefficient to estimate the correlation of individual peptides using age as a continuous variable. All peptides present in the full cohort were included in the correlation analysis since a frequency threshold was not set. The statistical significance was assumed at p-value less than 0.05. The p-value was adjusted by applying Benjamini-Hochberg [18] using an R-based statistical software (version 2.15.3). Generation of Box-Whisker plots and the Mann-Whitney test were performed and verified with MedCalc version 8.2.1.0 (MedCalc Software, Mariakerke, Belgium). MosaCluster (version 1.7.0) was used to build a classifier based on support vector machine (SVM) that allows the classification of samples in the high dimensional data space [19,20]. MosaCluster calculated classification scores based on the amplitudes of ageing peptides. Classification is performed by determining the Euclidian distance (defined as the SVM classification score) of the vector to a maximal margin hyperplane. The SVM-classifier uses the log transformed intensities of x features (peptides) as coordinates in an x-dimensional space. It then builds an x-1 dimensional hyperplane that spans this space by performing a quadratic programming optimisation of a Lagrangian using the training labels only while allowing for samples to lie on the wrong side of the plane. For such mistakes in classification the SVM introduces a cost parameter C. Because non separable problems in low dimensions may be separable in higher dimensions, the SVM uses the so called Kernel-trick to transform the samples to a higher dimensional space. MosaCluster uses the standard radial basis functions as kernel. These functions are just Gaussians with the parameter gamma controlling their width. There are generally implemented in SVMs in all popular data mining software, particularly the kernlab cran contributed R package is a versatile tool for building SVM based-classifiers [21]. After

identification of significant biomarkers and generation of different classifiers, they were assessed in a test set or a validation set to check their performance.

#### Orthology

Orthology between age-correlated mouse and human peptides was defined as follows: i) identical fragments, ii) peptides derived from the same protein region with a minimum overlap of 6 amino acids between the two species and iii) peptide sequences with a one amino acid gap [22]. In addition only peptides with the same correlation direction with age in mice and humans were retained.

#### Results

#### Identification of age-correlated peptides in mice

To identify peptides associated with ageing, the urinary proteome profiles of a cohort of 89 C57BL/6 wild-type mice were analysed by CE-MS (Fig 1). A correlation analysis of individual peptides with age was performed using age as a continuous variable and 295 peptides were significantly correlated with age ( $p \le 0.05$ ) (S1 Table). A considerable number of peptides (42%) associated to mouse ageing were fragments of different collagen proteins, similarly to what was observed in human ageing [7,8]. Additionally, some age-correlated peptides were only identified in mice including fragments of kidney androgen-regulated protein, complement factor D and pro-epidermal growth factor (S1 Table). Non collagen peptides were predominantly positively correlated with age and included fragments of kidney androgen-regulated protein, pro-epidermal growth factor, alpha-1-antitrypsin, major urinary protein, meprin A subunit alpha, complement factor D, uromodulin and serine protease inhibitor A3K whereas collagen fragments were predominantly negatively correlated with age and included collagen alpha-1(I) chain, collagen alpha-1(III) chain and collagen alpha-2(I) chain (S1 Table, see rho factor). The two most strongly negatively age-correlated peptides were collagen alpha-1(III) chain and collagen alpha-1(I) chain fragments (respectively  $\rho = -0.787$ , p< 0.0001 and  $\rho = -0.739$ , p< 0.0001 Table 1) whereas the two most strongly positively correlated peptides corresponded to E3 ubiquitin-protein ligase and a kidney and rogen-regulated protein fragments (respectively,  $\rho = 0.717$ , p < 0.0001 and  $\rho =$ 0.709, p< 0.0001 respectively Table 1).

## Assessment of urinary proteome similarity in wild-type mice and humans ageing: Individual peptides

We have recently identified urinary peptides related to human ageing [7]. Briefly, the urinary proteome of 1227 healthy individuals between (20–86 years old) was analysed and correlated with age. A total of 116 peptides predominantly made up of different collagen fragments (72%) were found to be associated to apparent healthy human ageing [7]. Collagen fragments were predominantly negatively correlated and comprised mainly collagen alpha-1(I) chain, collagen alpha-1(II) chain, and collagen alpha-2(I) chain whereas non collagen fragments were predominantly positively correlated and comprised for example fibrinogen fragments and uromodulin.

Since collagen fragments and uromodulin fragments were observed to be associated to both mouse and human ageing and represented the majority of the peptides, they were further used to evaluate the similarity between mouse and human ageing based on orthology analysis. Forty nine unique sequences in mice showed orthology to 42 unique sequences in humans, although 1 peptide in mice could have several corresponding ortholog peptides in humans and *vice* 







*versa* (Table 2, S2 Table). Ortholog sequences included collagen alpha-1(I) chain, collagen alpha-1(II) chain, collagen alpha-2(I) chain and uromodulin. Proteome profiles of the ortholog peptides in young and old wild-type mice and healthy subjects were depicted for visual representation. The decreased of collagen alpha-1(I) (respectively Figs 2 and 3, green stars) and the increased of uromodulin peptides (respectively Figs 2 and 3, red stars) with age were depicted. Overall, of the 295 peptides associated to mouse ageing, 49 displayed similarity with urinary peptides of human ageing in healthy individuals.

Rho factor	Adjusted p-value	Sequence	Protein name	Start AA	Stop AA
-0.787	3.08E-16	GSPGAKGEVGpAGSPGSNGSPGQRGEpGpQ	Collagen alpha-1(III) chain	344	373
-0.739	2.50E-13	GQpGAKGEpGDTGVKGDAGPpGP	Collagen alpha-1(I) chain	810	832
-0.680	9.48E-11	GQPGAKGEpGDTGVKGDAGPpGP	Collagen alpha-1(I) chain	810	832
-0.678	1.10E-10	ppGpAGAAGPAGNPGADGQpGAKG	Collagen alpha-1(I) chain	364	387
-0.620	620 2.14E-08 GLPGppGPpGEGGKQGDQ		Collagen alpha-1(I) chain	531	547
-0.582	-0.582 3.34E-7 GLPGppGPpGEGGKQGDQ   -0.577 4.5E-07 YKGmVGSIGAAGpPGEEGPRGppGEAG		Collagen alpha-1(II) chain	666	683
-0.577			EEGPRGppGEAG Collagen alpha-2(IX) chain		
-0.553	1.73E-06	DEAGSEAHREGETR	Fibrinogen alpha chain	527	540
-0.551	1.94E-06	KGTAGEpGKAG	Collagen alpha-1(I) chain	575	585
-05.47	2.51E-06	AGPpGPTGPTGPp	Collagen alpha-1(I) chain	320	332
0.543	2.98E-06	SLNEKLQN	Coiled-coil domain-containing protein 18	1069	1076
0.560	1.15E-06	ELQNSIIDLLNS	Kidney androgen-regulated protein	30	41
0.564	9.15E-7	VSINKELQNSII	Kidney androgen-regulated protein	25	36
0.572	5.99E-7	LVSINKELQNSIIDLLNS	Kidney androgen-regulated protein	24	41
0.597	1.15E-07	SINKELQNSIIDLLNS	Kidney androgen-regulated protein	26	41
0.599	1.07E-7	AAPEIILGNPV	Triple functional domain protein	2962	2972
0.694	2.54E-11	LVSINKELQNS	Kidney androgen-regulated protein	24	34
0.697	1.92E-11	EEHTQSPIFLGKVVDPTHK	Alpha-1-antitrypsin 1–1	395	413
0.709	6.35E-12	VSINKELQNS	Kidney androgen-regulated protein	25	34
0.717	3.00E-12	MPSLVVVSGGNSLNNLI	E3 ubiquitin-protein ligase HERC2	2846	2862

#### Table 1. The 20 best age-correlated peptides identified in mice.

In bold are negatively correlated peptides and positively correlated peptides are in italic. p = hydroxylated proline.

doi:10.1371/journal.pone.0166875.t001

# Assessment of urinary proteome similarity in wild-type mice and humans ageing: Use of multidimensional peptide models

To further investigate whether the mouse urinary peptides were representative of human ageing, we developed multidimensional classifiers based on the ortholog peptides. We scored mice and human age using these classifiers based on the hypothesis that correct age classification by these ortholog peptides in both mice and humans validates the translatability of the mouse peptides. With this aim, an ageing classifier was developed, using the 49 ortholog agecorrelated mouse peptides, along with a training cohort of wild-type mice (N = 39) using support vector machine (SVM)-based modelling. This resulted in the classifier called ACM49 (ACM: ageing classifier in mouse). To validate the classifier, a cohort of 45 wild-type mice including young (12 weeks; N = 15), mature (48 weeks; N = 15), and old (96 weeks; N = 15) were used. In this validation, the ACM49 classifier was able to discriminate between the different age groups with p < 0.0001 in young versus old; p = 0.0030 in young versus mature; and p = 0.0045 in mature versus old. As depicted in the Box-Whisker plot (Fig 4), the median scores from the ACM49 classifier increased proportionally to the age of wild-type mice. Additionally, ACM49 was also used to assess the age of telomerase knock out mice samples (N = 5). Findings revealed that classification scores of 61 weeks old telomerase knock out mice were significantly higher (p = 0.0019) than of 96 weeks old wild-type mice (Fig 4).

The same peptides, but now ortholog in humans, comprised of 42 peptides (S2 Table) were modelled in a classifier called ACH42 (ACH: ageing classifier in human) using a training human cohort of healthy subjects (N = 50). To validate the classifier, an independent cohort of 60 healthy subjects including young (20–39 years; N = 20), mature (40–59 years; N = 20) and old (60 years and over; N = 20) were used. In this independent validation the ACH42 classifier

#### Table 2. Ortholog peptides identified in mice and humans.

Peptide ID mice	Sequence mice	Peptide ID humans	Sequence humans	Gene symbol
1504650	<b>GPpGKNGDDGEAGKpGRp</b> GERGPpGP	68411	Pp <b>GPpGKNGDDGEAGKpGRp</b>	COL1A1
16415	<b>KNGDDGEAGKpG</b> RpG	41476	GPPG <b>kngddgeagkpg</b>	COL1A1
1504057	KNGDDGEAGKpGRpGERGPpGP <sup>1</sup>	102819	GPpG <b>KNGDDGEAGKPGRpGERGPpGp</b> Q	COL1A1
1504810	<b>KNGDDGEAGKpG</b> RPGERGpPGP	38011	PpG <b>KNGDDGEAGKpG</b>	COL1A1
19556	GEAGKPGRpGERGPpGP <sup>2</sup>	93897	PpGKNGDD <b>GEAGKPGRpGERGppGP</b>	COL1A1
19556	GEAGKPGRpGERGPpGP <sup>2</sup>	99919	PpGKNGDD <b>GEAGKPGRpGERGppGP</b> Q	COL1A1
6931	GRpGERGPpGP	87365	KNGDDGEAGKP <b>GRPGERGPPGP</b> Q	COL1A1
1504057	KNGDDGEAGKpGRpGERGPpGP <sup>1</sup>	89642	<b>KNGDDGEAGKPGRpGERGPPGp</b> QG	COL1A1
7545	AGPpGPTGPTGPp <sup>3</sup>	141007	ARGNDGATGA <b>AGPpGPTGP</b> A <b>Gpp</b> GFpGAVGAKGEAGPQGPRG	COL1A1
7545	AGPpGPTGPTGPp <sup>3</sup>	155132	ARGNDGATGA <b>AGpPGPTGP</b> A <b>GPP</b> GFpGAVGAKGEAGpQGpRGSEGPQG	COL1A1
37057	NSGEpGApGNKGDTGAKGEpGATGVQGPpGP	50172	ApgSKGDTGAKGEpGPVG	COL1A1
18625	TG <b>SpGSPGPDGKTGPp</b> GP	29538	SpGSPGPDGKTGPp	COL1A1
18875	TGSpGSpGPDGKTGPpGP	46649	$SpGSPGPDGKTGPpGPAG^7$	COL1A1
20909	TG <b>SpGSPGPDGKTGPpGPAG</b>	46649	SpGSPGPDGKTGPpGPAG <sup>7</sup>	COL1A1
16583	GSpGSPGPDGKTGPpGP	29538	SpGSPGPDGKTGPp <sup>8</sup>	COL1A1
16886	G <b>SpGSpGPDGKTGPp</b> GP	29538	SpGSPGPDGKTGPp <sup>8</sup>	COL1A1
19345	GSpGSpGPDGKTGPpGPAG	46649	SpGSPGPDGKTGPpGPAG <sup>7</sup>	COL1A1
18066	SpGSPGPDGKTGPpGPAG	46649	SpGSPGPDGKTGPpGPAG <sup>7</sup>	COL1A1
3902	KGTAGEpGKAG	117371	VMGFPGp <b>KG</b> A <b>GEPGKAG</b> ERGVpGppGAVGPAG	COL1A1
1506170	TAGEpGKAGERGLpGPpG <sup>4</sup>	122825	GEpGKAGERGVpGPPGAVGpAGKDGEAGAQGPPGP	COL1A1
1506170	TAGEpGKAGERGLpGPpG <sup>4</sup>	127351	A <b>AGEPGKAGERG</b> V <b>pGPpG</b> AVGPAGKDGEAGAQGPPGP	COL1A1
1505741	ERGEQGPAGSpG	135166	ERGEQGPAGSpGFQGLpGPAGPpGEAGKpGEQGVPGD	COL1A1
19814	GLPGpAGPpGEAGKpGEQ	100255	GLPGpAGppGEAGKPGEQGVPGDLGApGP <sup>9</sup>	COL1A1
4170	KpGEQGVPGD	100255	GLPGpAGppGEAG <b>KPGEQGVPGD</b> LGApGP <sup>9</sup>	COL1A1
17232	KpGEQGVpGDLGApGP	100255	GLPGpAGppGEAG <b>KPGEQGVPGDLGApGP</b> <sup>9</sup>	COL1A1
16079	GQPGAKGEpGDTGVKG	92841	AD <b>GQPGAKGEpGD</b> AGAKGDAGPpGPAGP <sup>10</sup>	COL1A1
26939	GQPGAKGEpGDTGVKGDAGPpGP	121241	AD <b>GQPGAKGEpGD</b> AGAKGDAGPpGPAGPAGPPGPIG	COL1A1
27161	G <b>QpGAKGEpGD</b> TGVKGDAGPpGP	28850	DG <b>QPGAKGEpGD</b> AG	COL1A1
27388	G <b>QpGAKGEpGD</b> TGVKGDAGppGP	40344	DG <b>QPGAKGEPGD</b> AGAK	COL1A1
9877	PGAKGEpGDTGVK	44802	DGQ <b>PGAKGEpGD</b> AGAKG	COL1A1
14420	<b>PGAKGEpGD</b> TGVKGD	92841	ADGQ <b>PGAKGEpGD</b> AGAKGDAGPpGPAGP <sup>10</sup>	COL1A1
24239	ETGPAGRpGEVGPpGPpGPAG	140803	ETGPAGRpGEVGPpGpPGPAGEKGSPGADGPAGAPGTPGPQG <sup>11</sup>	COL1A1
20667	GEVGPpGPpGpAGEKGSpG	140803	ETGPAGRP <b>GEVGPpGpPGPAGEKGSPG</b> ADGPAGAPGTPGPQG <sup>11</sup>	COL1A1
38376		127432	GPpG <b>ESGREG</b> A <b>PGAEGSpGRDG</b> S <b>pGAKGDRGETGp</b>	COL1A1
35125	REGSpGAEGSpGRDGApGAKGDRGETGP <sup>5</sup>	130077	GPpGESG <b>REGApGAEGSpGRDG</b> S <b>pGAKGDRGETGP</b> A	COL1A1
35125	REGSpGA <b>EGSpGRDG</b> A <b>pGAKGDRG</b> ETGP <sup>5</sup>	51175	EGSpGRDGSpGAKGDRG	COL1A1
10361	DGAp <b>GAKGDRGET</b>	124886	Ppgesgregapgaegspgrdgsp <b>gakgdrget</b> gp	COL1A1
17249	pGPVGPAGKNGDRGET	128435	DRGETGPAGPpGApGAPGAPGA <b>PGPVGpAGK</b> S <b>GDRGET</b> GP	COL1A1
25169	- QGI <b>pGTGGPpGENGKpGEpGP</b>	16910	GLpGTGGPpGENGKPGEPGp	COL3A1
15377	GIpGTGGPpGENGKpG	61304	GL <b>pGTGGPpGENGKpG</b> EPGpKG <sup>12</sup>	COL3A1
12858	GPpGENGKpGEpGP	61304	GLpGTG <b>GPpGENGKpGEPGp</b> KG <sup>12</sup>	COL3A1
31210	QNGEpGAKGERGApGEKGEGGPpGP	70911	GAPGQ <b>NGEPG</b> G <b>kGERGApGEKGEGGPpG</b>	COL3A1
27744	GEDGAKGERG <b>ADGEKGEGGPDGP</b>	97638	Apgekgeggppg <sup>13</sup>	COL3A1
8738		97638	Apgekgeggppg <sup>13</sup>	COL3A1
1505438	ApGLpGPRGIpGPAG	126318	TGAKGAAGLpGVAG <b>ApGLpGPRGIpGP</b> VGAAGATGARG	COL1A2
1506234	KGEO <b>GDAGP</b> PGFOGLpG	138279	EVGKpGERGIHGEFGIp <b>GPAGpRG</b> ERGPPGESGAAGP	COL1A2
	~ ~			

(Continued)

#### Table 2. (Continued)

Peptide ID mice	Sequence mice	Peptide ID humans	Sequence humans	Gene symbol
30714	SGTTG <b>EVGKpGERGL</b> p <b>GEFGLpGP</b>	148645	EVGKpGERGLHGEFGLPGPAGpRGERGpPGESGAAGPTGPIG	COL1A2
27017	DGPpGRDGQpGHKGERGYpG <sup>6</sup>	112515	GRDGNpGN <b>DGPpGRDGQpGHKGERGYpG</b>	COL1A2
27017	DGPpGRDGQpGHKGERGYpG <sup>6</sup>	80306	NDGPpGRDGQpGHKGERGYpG	COL1A2
36597	PGKDGEVGPSGPVGPPGLAGERGEQGppGP	113351	GpSGpVGpPGLAGERGEQGPpGPTGFQGLPG	COL5A2
25768	SGNF <b>IDQ</b> T <b>RVLNLGPI</b> TR	53181	SGSV <b>IDQ</b> S <b>RVLNLGPI</b>	UMOD
6864	FIDQTRVLN	43605	SVIDQS <b>RVLN</b> LGPI	UMOD
18643	IDQTRVLNLGPITR	50056	SVIDQSRVLNLGPIT <sup>14</sup>	UMOD
16362	DQTRVLNLGPITR	50056	SVIDQSRVINLGPIT <sup>14</sup>	UMOD
3736	VLNLGPITR	50056	SVIDQSR <b>VINLGPIT<sup>14</sup></b>	UMOD

The superscripted numbers represent sequences that have several ortholog in either mice or humans. In bold are the ortholog sequences. p = hydroxylated proline.

doi:10.1371/journal.pone.0166875.t002

was able to discriminate between the different age groups with p = 0.0005 in young vs old; p < 0.0001 in young vs mature; and p = 0.0453 in mature vs old. The classifier was significantly able to discriminate between different age groups as younger subjects had a lower median score generated by the ACH42 classifier which progressively increased with age (Fig 5). The data suggested that urinary peptide classifiers exclusively comprising ortholog peptides, can discriminate the age in both species.



Fig 2. Abundance of ortholog peptides in wild-type mice. (A) Young mice (4 weeks old) and (B) wild-type old mice (84 weeks old). The green stars represent collagen alpha-1(I) chain peptides where as the red stars represent uromodulin peptides.

doi:10.1371/journal.pone.0166875.g002





Fig 3. Abundance of ortholog peptides in healthy subjects. (A) Young subjects (20–39 years old) and (B) healthy old subjects in (60 years old and over). The green stars represent collagen alpha-1(I) chain peptides where as the red stars represent uromodulin peptides.

#### Discussion

The urinary proteome profiles of 89 wild-type mice were analysed and compared with the proteome profiles of a unique cohort of 1227 healthy subjects to evaluate the translatability of ageing findings from mice to humans.

Using urinary proteomics, common molecular mechanisms describing ageing in human and mouse were identified. The difference in the number of identified peptides (295 versus 116) between mice and humans most likely lies in the high genetic variability in humans and their exposure to environmental changes leading to age-dependent changes being obstructed. Therefore, the great biological variance resulted in a lower number of biomarkers. In both species, a decrease in collagen fragments and increase in uromodulin peptides were identified as key molecular changes observed during ageing. These ortholog peptides which predominantly included collagens fragments were able to discriminate among different age groups in both human and mouse cohorts. These findings not only highlight the translatability from mice to humans, but also specifically point out that this translatability is mostly attributed to collagens. Thus, findings highlight the key role of collagens in human and mouse ageing processes.

Indeed, the pivotal role of collagens in ageing has previously been shown [3,7,8]. However, the strong homology in mouse and human collagens in ageing via investigation of the urinary proteome has not been shown before. This observation suggests that mice can be used to assess anti-ageing interventions targeting collagens [23] in humans. As a disturbance in the collagen homeostasis is associated with several chronic age-related conditions including cancers [24], chronic kidney diseases (CKD) [25] and cardiovascular diseases [26], mice can also be used to develop therapeutic interventions for humans against these age-associated pathologies.



Fig 4. Box-whisker plot depicting the age classification in wild-type and telomerase knock-out mice. \* Statistically significant p-value, WT: wild-type, Terc<sup>-/-</sup>: telomerase knock-out mice and w: weeks.

ONE

PLOS

Furthermore, the identification of age-correlated ortholog peptides enables to gain increased insight into molecular mechanisms involved during human and mouse ageing. In humans, ageing was characterised by the decrease of fibrillary collagen fragments, especially collagen alpha-1(I) chain, collagen alpha-1(III) chain and collagen alpha-2(I) chain. The reduction in collagen type I and type III synthesis has previously been associated to skin ageing [27] and to systemic ageing [7,8]. Indeed, a reduction in collagen synthesis may indicate a perturbation in the extracellular matrix (ECM) remodelling. The ECM is ubiquitous in the organism and plays a pivotal role in tissue elasticity and integrity [28]. Perturbations of the ECM have been associated with several pathologies [28]. For instance, perturbations in the ECM have been shown to cause fibrosis; a condition characterised by an abnormal accumulation of ECM components. Fibrosis has been associated with renal diseases, cardiovascular diseases and cancers [29]. Hence in humans, ageing is characterised by a perturbation in collagen homeostasis which can lead to fibrosis formation followed by a myriad of age-related complications.

In mice, the urinary excretion of fibrillar type I and III collagen fragments representing the majority of collagenous peptides decreased with increasing age. This may be reflective of



Fig 5. Box-whisker plot depicting the age classification in healthy subjects. Young subjects are between 20–39 years, mature subjects are between 40–59 years and old subjects are 60 years old and over. \* Statistically significant p-value.

PLOS ONE

increased cross-linking and subsequently increased collagen biosynthesis and decreased activity of matrix metalloproteinases and other collagen degrading enzymes [30]. In a recent study, a mouse model developing resistance to type I collagenase activity ( $Col1a1^{r/r}$ ) was demonstrated to promote premature ageing [31]. The Collal<sup>r/r</sup> mice were shown to have shortened lifespan in comparison to WT mice and they developed hypertension caused by aortic stiffness. Interestingly, collagenase-resistant collagen was reported to promote premature ageing by inducing senescence in vascular smooth muscle cells due to inadequate communication with  $\alpha\nu\beta3$  integrin [31]. Moreover, a type III collagen-deficient mouse was generated to assess bladder function [32]. It was shown in this study that deficiency in type III collagen fragment caused reduced tension or elasticity subsequently resulting in impaired bladder contraction and development [32]. In humans, resistance in collagen degradation by collagenases has been previously shown to predict the chronological age using diaphragm tissues obtained from biopsies [33]. In addition to collagen fragments, uromodulin was shown to increase with age. Uromodulin is a protein exclusively produced in the kidney and the most abundant protein in urine. Its biological function still remains unknown however; deregulation in its synthesis has been reported to be associated with hypertension and chronic kidney diseases [34].

Ageing classifiers were established based on ortholog peptides and these classifiers could discriminate the age in both humans and wild-type mice. Hence, these findings demonstrate the translatability of results from mouse to human based on urinary proteome analysis. Similar observations were also made while using urinary proteome analysis to compare between rat and human in a previous study [35]. It was observed that the ZDF rat model for type 2 diabetes mellitus displayed similarity to human cardiovascular diseases rather than chronic kidney diseases based on ortholog peptides [35]. Furthermore, the mouse ageing classifier ACM49 was able to discriminate the age in wild-type mice and also the internal age in telomerase knockout (Terc<sup>-/-</sup>) mouse models characterised by a short lifespan. The ACM49 revealed a discrepancy between the chronological age of Terc<sup>-/-</sup> and their internal age as the 61 weeks old Terc<sup>-/-</sup> mouse models had higher scores compared to 96 weeks WT mice. Though findings in mice are translatable in humans when focusing on ortholog peptides, this observation cannot be generalised to all identified age-related peptides. Indeed looking at the differences in the number of identified peptides, and also looking at the unique peptides specific to each species, it is obvious that findings using mouse models must be interpreted with care.

In conclusion, we have demonstrated that mice can be good models to study human ageing when focusing on ortholog peptides. One major advantage of using urinary proteomics to study ageing, as suggested by the results, is the ability to obtain a representative readout of human ageing using mouse models, hence, allowing eventually to investigate interventions in the management of ageing-associated complications.

#### **Supporting information**

**S1 Table. Age-correlated peptides identified in wild-type mice.** 1 means human, 2 means mouse and 1, 2 means human and mouse. (XLS)

**S2 Table. Ortholog peptides identified in mice and humans.** The superscripted numbers represent sequences that have several ortholog in either mice or humans. In bold are the ortholog sequences. (XLS)

#### **Author Contributions**

Conceptualization: ENK JPS AP HM PZ. Data curation: ENK PZ. Formal analysis: ENK JPS AP AV PZ. Funding acquisition: HM TBH KLR. Investigation: ENK. Methodology: ENK MP TK HM JPS PZ. Project administration: PZ. Resources: HM JPS CD PV JLB MB HB WBW TBH KLR. Supervision: JSP HM PZ. Validation: ENK SB CD PV JLB PZ. Writing – original draft: ENK SB TK JPS PZ. Writing – review & editing: ENK JPS SB MP CV CD PV JLB AV TK MB HB WBW TBH KLR AP HM PZ.

#### References

- 1. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G (2013) The hallmarks of aging. Cell 153: 1194–1217. doi: 10.1016/j.cell.2013.05.039 PMID: 23746838
- Prince MJ, Wu F, Guo Y, Gutierrez Robledo LM, O'Donnell M, Sullivan R, Yusuf S (2015) The burden of disease in older people and implications for health policy and practice. Lancet 385: 549–562. doi: 10. 1016/S0140-6736(14)61347-7 PMID: 25468153
- Nkuipou-Kenfack E, Koeck T, Mischak H, Pich A, Schanstra JP, Zurbig P, Schumacher B (2014) Proteome analysis in the assessment of ageing. Ageing Res Rev 18C: 74–85.
- 4. Burkhardt AM, Zlotnik A (2013) Translating translational research: mouse models of human disease. Cell Mol Immunol 10: 373–374. doi: 10.1038/cmi.2013.19 PMID: 23934028
- Dissard R, Klein J, Caubet C, Breuil B, Siwy J, Hoffman J, Sicard L, Ducassé L, Rascalou S, Payre B, Buléon M, Mullen W, Mischak H, Tack I, Bascands JL, Buffin-Meyer B, Schanstra JP, (2013) Long Term Metabolic Syndrome Induced by a High Fructose Diet Leads to Minimal Renal Injury in C57BL/6 Mice model for human disease based on urinary peptidomic profiles. PLoS One 8: e76703.
- Klein J, Ramirez-Torres A, Ericsson A, Huang Y, Breuil B, Siwy J, Mischak H, Peng XR, Bascands JL, Schanstra JP, (2016) Urinary peptidomics provides a noninvasive humanized readout of diabetic nephropathy in mice. Kidney Int.
- Nkuipou-Kenfack E, Bhat A, Klein J, Jankowski V, Mullen W, Vlahou A, Dakna M, Koeck T, Schanstra JP, Zurbig P, Rudolph KL, Schumacher B, Pich A, Mischak H (2015) Identification of ageing-associated naturally occurring peptides in human urine. Oncotarget.
- Zürbig P, Decramer S, Dakna M, Jantos J, Good DM, Coon JJ, Bandin F, Mischak H, Bascands JL, Schanstra J (2009) The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease. Proteomics 9: 2108–2117. doi: 10.1002/pmic.200800560 PMID: 19296547
- Herrera E, Samper E, Martin-Caballero J, Flores JM, Lee HW, Blasco MA (1999) Disease states associated with telomerase deficiency appear earlier in mice with short telomeres. EMBO J 18: 2950–2960. doi: 10.1093/emboj/18.11.2950 PMID: 10357808
- Rudolph KL, Chang S, Lee HW, Blasco M, Gottlieb GJ, Greider C, DePinho RA (1999) Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell 96: 701–712. PMID: 10089885
- Mischak H, Schanstra JP (2011) CE-MS in biomarker discovery, validation, and clinical application. Proteomics Clin Appl 5: 9–23. doi: 10.1002/prca.201000058 PMID: 21280234
- 12. Arab S, Gramolini AO, Ping P, Kislinger T, Stanley B, Van EJ, Ouzounian M, Maclennan DH, Emili A, Liu PP (2006) Cardiovascular proteomics: tools to develop novel biomarkers and potential applications. J Am Coll Cardiol 48: 1733–1741. doi: 10.1016/j.jacc.2006.06.063 PMID: 17084242
- Zürbig P, Renfrow M.B., Schiffer E, Novak J, Walden M, Wittke S, Just I, Pelzing M, Neususs C, Theodorescu D, Root C, Ross M, Mischak H (2006) Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis 27: 2111–2125. doi: 10.1002/ elps.200500827 PMID: 16645980
- 14. Schanstra JP, Zurbig P, Alkhalaf A, Argiles A, Bakker SJ, Beige J, Bilo HJ, Chatzikyrkou C, Dakna M, Dawson J, Delles C, Haller H, Haubitz M, Husi H, Jankowski J, Jerums G, Kleefstra N, Kuznetsova T, Maahs DM, Menne J, Mullen W, Ortiz A, Persson F, Rossing P, Ruggenenti P, Rychlik I, Serra AL, Siwy J, Snell-Bergeon J, Spasovski G, Staessen JA, Vlahou A, Mischak H, Vanholder R (2015) Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. J Am Soc Nephrol.
- 15. von zur Muhlen C, Schiffer E, Sackmann C, Zurbig P, Neudorfer I, Zirlik A, Htun N, Iphofer A, Jansch L, Mischak H, Bode C, Chen YC, Peter K (2012) Urine proteome analysis reflects atherosclerotic disease in an ApoE-/- mouse model and allows the discovery of new candidate biomarkers in mouse and human atherosclerosis. Mol Cell Proteomics 11: M111.
- 16. Gu YM, Thijs L, Liu YP, Zhang Z, Jacobs L, Koeck T, Zurbig P, Lichtinghagen R, Brand K, Kuznetsova T, Olivi L, Verhamme P, Delles C, Mischak H, Staessen JA (2014) The urinary proteome as correlate and predictor of renal function in a population study. Nephrol Dial Transplant.
- Vizcanío JA, Csordas A, del-Toro N, Dianes JA, Griss J, Lavidas I, Mayer G, Perez-Riverol Y, Reisinger F, Ternent T, Xu QW, Wang R, Hermjakob H (2016) 2016 update of the PRIDE database and related tools. Nucleic Acids Res 44: D447–D456. doi: 10.1093/nar/gkv1145 PMID: 26527722
- Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc B (Methodological) 57: 125–133.

- Girolami M, Mischak H, Krebs R (2006) Analysis of complex, multidimensional datasets. Drug Discov Today: Technologies 3: 13–19. doi: 10.1016/j.ddtec.2006.03.010 PMID: 24980097
- 20. Yang ZR (2004) Biological applications of support vector machines. Brief Bioinform 5: 328–338. PMID: 15606969
- **21.** R Development Core Team (2008) R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing.
- 22. Siwy J, Zoja C, Klein J., Benigni A, Mullen W, Mayer B, Mischak H, Jankowski J, Stevens R, Vlahou A, Kossida S, Perco P, Bahlmann F (2012) Evaluation of the Zucker Diabetic Fatty (ZDF) rat as a model for human disease based on urinary
- Ganceviciene R, Liakou AI, Theodoridis A, Makrantonaki E, Zouboulis CC (2012) Skin anti-aging strategies. Dermatoendocrinol 4: 308–319. doi: 10.4161/derm.22804 PMID: 23467476
- Lu P, Weaver VM, Werb Z (2012) The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 196: 395–406. doi: 10.1083/jcb.201102147 PMID: 22351925
- Genovese F, Manresa AA, Leeming DJ, Karsdal MA, Boor P (2014) The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis? Fibrogenesis Tissue Repair 7: 4. doi: 10.1186/1755-1536-7-4 PMID: 24678881
- 26. Rodriguez-Feo JA, Sluijter JP, de Kleijn DP, Pasterkamp G (2005) Modulation of collagen turnover in cardiovascular disease. Curr Pharm Des 11: 2501–2514. PMID: 16026303
- Varani J, Dame MK, Rittie L, Fligiel SE, Kang S, Fisher GJ, Voorhees JJ (2006) Decreased collagen production in chronologically aged skin: roles of age-dependent alteration in fibroblast function and defective mechanical stimulation. Am J Pathol 168: 1861–1868. doi: 10.2353/ajpath.2006.051302 PMID: 16723701
- Bonnans C, Chou J, Werb Z (2014) Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol 15: 786–801. doi: 10.1038/nrm3904 PMID: 25415508
- Wynn TA (2007) Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest 117: 524–529. doi: 10.1172/JCI31487 PMID: 17332879
- 30. van der Slot-Verhoeven AJ, van Dura EA, Attema J, Blauw B, Degroot J, Huizinga TW, Zuurmond AM, Bank RA (2005) The type of collagen cross-link determines the reversibility of experimental skin fibrosis. Biochim Biophys Acta 1740: 60–67. doi: 10.1016/j.bbadis.2005.02.007 PMID: 15878742
- Vafaie F, Yin H, O'Neil C, Nong Z, Watson A, Arpino JM, Chu MW, Wayne HD, Gros R, Pickering JG (2014) Collagenase-resistant collagen promotes mouse aging and vascular cell senescence. Aging Cell 13: 121–130. doi: 10.1111/acel.12155 PMID: 23957394
- Stevenson K, Kucich U, Whitbeck C, Levin RM, Howard PS (2006) Functional changes in bladder tissue from type III collagen-deficient mice. Mol Cell Biochem 283: 107–114. doi: <u>10.1007/s11010-006-2388-</u> 1 PMID: 16444592
- **33.** Hamlin CR, Kohn RR (1972) Determination of human chronological age by study of a collagen sample. Exp Gerontol 7: 377–379. PMID: 4345626
- Rampoldi L, Scolari F, Amoroso A, Ghiggeri G, Devuyst O (2011) The rediscovery of uromodulin (Tamm-Horsfall protein): from tubulointerstitial nephropathy to chronic kidney disease. Kidney Int 80: 338–347. doi: 10.1038/ki.2011.134 PMID: 21654721
- 35. Siwy J, Zoja C, Klein J, Benigni A, Mullen W, Mayer B, Mischak H, Jankowski J, Stevens R, Vlahou A, Kossida S, Perco P, Bahlmann F (2012) Evaluation of the Zucker Diabetic Fatty (ZDF) rat as a model for human disease based on urinary peptidomic profiles. PLoS One 7: e51334. doi: 10.1371/journal. pone.0051334 PMID: 23236474